These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 18519778)

  • 1. A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
    Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM
    Clin Cancer Res; 2008 Jun; 14(11):3462-9. PubMed ID: 18519778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
    Robertson MJ; Mier JW; Logan T; Atkins M; Koon H; Koch KM; Kathman S; Pandite LN; Oei C; Kirby LC; Jewell RC; Bell WN; Thurmond LM; Weisenbach J; Roberts S; Dar MM
    Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4265-73. PubMed ID: 16857801
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphoma.
    Robertson MJ; Kline J; Struemper H; Koch KM; Bauman JW; Gardner OS; Murray SC; Germaschewski F; Weisenbach J; Jonak Z; Toso JF
    J Immunother; 2013; 36(6):331-41. PubMed ID: 23799412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB; Robertson MJ; Gordon M; Lotze MT; DeCoste M; DuBois JS; Ritz J; Sandler AB; Edington HD; Garzone PD; Mier JW; Canning CM; Battiato L; Tahara H; Sherman ML
    Clin Cancer Res; 1997 Mar; 3(3):409-17. PubMed ID: 9815699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.
    Robertson MJ; Stamatkin CW; Pelloso D; Weisenbach J; Prasad NK; Safa AR
    J Immunother; 2018 Apr; 41(3):151-157. PubMed ID: 29517616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma.
    Gollob JA; Veenstra KG; Parker RA; Mier JW; McDermott DF; Clancy D; Tutin L; Koon H; Atkins MB
    J Clin Oncol; 2003 Jul; 21(13):2564-73. PubMed ID: 12829677
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial.
    Heery CR; O'Sullivan-Coyne G; Madan RA; Cordes L; Rajan A; Rauckhorst M; Lamping E; Oyelakin I; Marté JL; Lepone LM; Donahue RN; Grenga I; Cuillerot JM; Neuteboom B; Heydebreck AV; Chin K; Schlom J; Gulley JL
    Lancet Oncol; 2017 May; 18(5):587-598. PubMed ID: 28373007
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer.
    Conlon KC; Lugli E; Welles HC; Rosenberg SA; Fojo AT; Morris JC; Fleisher TA; Dubois SP; Perera LP; Stewart DM; Goldman CK; Bryant BR; Decker JM; Chen J; Worthy TA; Figg WD; Peer CJ; Sneller MC; Lane HC; Yovandich JL; Creekmore SP; Roederer M; Waldmann TA
    J Clin Oncol; 2015 Jan; 33(1):74-82. PubMed ID: 25403209
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response.
    Gollob JA; Mier JW; Veenstra K; McDermott DF; Clancy D; Clancy M; Atkins MB
    Clin Cancer Res; 2000 May; 6(5):1678-92. PubMed ID: 10815886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A dose-escalation and pharmacokinetic study of subcutaneously administered recombinant human interleukin 12 and its biological effects in Japanese patients with advanced malignancies.
    Ohno R; Yamaguchi Y; Toge T; Kinouchi T; Kotake T; Shibata M; Kiyohara Y; Ikeda S; Fukui I; Gohchi A; Sugiyama Y; Saji S; Hazama S; Oka M; Ohnishi K; Ohhashi Y; Tsukagoshi S; Taguchi T
    Clin Cancer Res; 2000 Jul; 6(7):2661-9. PubMed ID: 10914707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.
    Sosman JA; Aronson FR; Sznol M; Atkins MB; Dutcher JP; Weiss GR; Isaacs RE; Margolin KA; Fisher RI; Ernest ML; Mier J; Oleksowicz L; Eckhardt JR; Levitt D; Doroshow JH
    Clin Cancer Res; 1997 Jan; 3(1):39-46. PubMed ID: 9815535
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 1 trial of recombinant human interleukin-1 beta (rhIL-1 beta), carboplatin, and etoposide in patients with solid cancers: Southwest Oncology, Group Study 8940.
    Rinehart J; Hersh E; Issell B; Triozzi P; Buhles W; Neidhart J
    Cancer Invest; 1997; 15(5):403-10. PubMed ID: 9316621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma.
    Davis ID; Skrumsager BK; Cebon J; Nicholaou T; Barlow JW; Moller NP; Skak K; Lundsgaard D; Frederiksen KS; Thygesen P; McArthur GA
    Clin Cancer Res; 2007 Jun; 13(12):3630-6. PubMed ID: 17575227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I trial of intravenous cisplatin-topotecan chemotherapy for three consecutive days in patients with advanced solid tumors: parallel topotecan escalation in two fixed platinum dosing schemes.
    Pentheroudakis G; Briasoulis E; Karavassilis V; Mauri D; Tzamakou E; Rammou D; Pavlidis N
    Chemotherapy; 2005 May; 51(2-3):154-61. PubMed ID: 15886476
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.
    Leonard JP; Sherman ML; Fisher GL; Buchanan LJ; Larsen G; Atkins MB; Sosman JA; Dutcher JP; Vogelzang NJ; Ryan JL
    Blood; 1997 Oct; 90(7):2541-8. PubMed ID: 9326219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer.
    Herbst RS; Eckhardt SG; Kurzrock R; Ebbinghaus S; O'Dwyer PJ; Gordon MS; Novotny W; Goldwasser MA; Tohnya TM; Lum BL; Ashkenazi A; Jubb AM; Mendelson DS
    J Clin Oncol; 2010 Jun; 28(17):2839-46. PubMed ID: 20458040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J; Margolin KA; Triozzi P; Hersh E; Campion M; Resta D; Levitt D
    Clin Cancer Res; 1995 Oct; 1(10):1139-44. PubMed ID: 9815905
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG; Eder JP; Ryan DP; Seiden MV; Lynch TJ; Amrein PC; Kufe DW; Clark JW
    Clin Cancer Res; 2003 Nov; 9(14):5178-86. PubMed ID: 14613997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors.
    Izquierdo MA; Bowman A; García M; Jodrell D; Martinez M; Pardo B; Gómez J; López-Martin JA; Jimeno J; Germá JR; Smyth JF
    Clin Cancer Res; 2008 May; 14(10):3105-12. PubMed ID: 18483378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of recombinant human interleukin-3 in patients with relapsed small-cell lung cancer treated with chemotherapy: a dose-finding study.
    Postmus PE; Gietema JA; Damsma O; Biesma B; Limburg PC; Vellenga E; de Vries EG
    J Clin Oncol; 1992 Jul; 10(7):1131-40. PubMed ID: 1318953
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.